There have been few trials of prophylactic granulocyte colony-stimulating factor (G-CFS) administration in patients with CLL while undergoing treatment with the R-FC regimen, although reducing febrile neutropenia during chemotherapy would be as beneficial as successful completion of the R-FC regimen. The gene discussed is CSF3; the disease is B-cell chronic lymphocytic leukemia.